• Explore /
  • Poster
  • / First-in-human phase I study of EGF816, a third<sup></sup> generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Abstract Poster

Authors

null

Daniel Shao-Weng Tan

National Cancer Centre Singapore, Singapore, Singapore

Daniel Shao-Weng Tan , Takashi Seto , Natasha B. Leighl , Gregory J. Riely , Lecia V. Sequist , Enriqueta Felip , Juergen Wolf , James Chih-Hsin Yang , Igor Matushansky , Xiaolu Yu , Shu-Fang Hsu Schmitz , Xiaoming Cui , Dong-Wan Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02108964

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8013)

DOI

10.1200/jco.2015.33.15_suppl.8013

Abstract #

8013

Poster Bd #

335

Abstract Disclosures

Similar Posters

First Author: Daniel Shao-Weng Tan

First Author: Rosario García Campelo

First Author: Jonathan W. Goldman

First Author: Li Zhang